Company overview
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing RLAY with another company.
| Daily close (USD) | $17.41 |
| Market capitalization (USD) | $3,815,255,795.71 |
| Price / earnings (TTM) | Not reported |
| Price / book | 4.29 |
No matching rows. Clear the filter to see all records.
Read RLAY's valuation metrics
Company size
Relay Therapeutics, Inc. Common Stock's recorded market capitalization is $3,815,255,795.71. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
RLAY's recorded price-to-book ratio is 4.29. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Relay Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about RLAY. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RLAY's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.